Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.36 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221670 | 1.00 | PDE5A (0.40) | PDE5AADORA3KCNH2AURKAPDPK1 | |
| SCHEMBL2878454 | 1.00 | PDE5A (0.40) | PDE5AADORA3KCNH2AURKAPDPK1 | |
| SCHEMBL8220418 | 0.91 | ADORA3 (0.46) | PDE5AADORA3KCNH2ATMKDM4E | |
| SCHEMBL2883924 | 0.91 | ADORA3 (0.46) | PDE5AADORA3KCNH2ATMKDM4E | |
| SCHEMBL2883926 | 0.91 | ADORA3 (0.46) | PDE5AADORA3KCNH2ATMKDM4E | |
| SCHEMBL2878213 | 0.89 | L3MBTL1 (0.39) | PDE5AADORA3KCNH2CFDL3MBTL1 | |
| SCHEMBL2878209 | 0.89 | L3MBTL1 (0.39) | PDE5AADORA3KCNH2CFDL3MBTL1 | |
| SCHEMBL8226875 | 0.89 | L3MBTL1 (0.39) | PDE5AADORA3KCNH2CFDL3MBTL1 | |
| SCHEMBL2878089 | 0.87 | KDM4E (0.38) | PDE5AADORA3KCNH2CFDATM | |
| SCHEMBL8229309 | 0.87 | KDM4E (0.38) | PDE5AADORA3KCNH2CFDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | PDE5A 984/4885ADORA3 492/4885KCNH2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.